Yantai Lannacheng Biotechnology Co., Ltd. (hereinafter referred to as LNC), headquartered in the beautiful beach city of Yantai, was jointly founded in 2021 by Yantai Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as DC Pharma), one of China’s leading nuclear medicine enterprises, and Professor Xiaoyuan (Shawn) Chen, a world expert in molecular imaging and nanomedicine. LNC Pharma Pte. Ltd. is its Singapore subsidiary in handling international affairs. LNC is committed to the global radiotheranostics R&D and registration, which form a critical part of DC Pharma’s nuclear medicine ecosystem.

LNC owns a large-scale comprehensive laboratory located in “Yantai MediPark Extra Space”, built in 2023 with an investment of over 100 million RMB, with about 6,500 m² lab space, capable of drug synthesis, radiolabeling, preclinical study, molecular imaging, and therapy experiments, marking the establishment of LNC’s “molecular screening and translational medicine core technology platform”, which will greatly advance the R&D process of LNC’s innovative radiopharmaceuticals.

LNC developed a series of proprietary long-acting radiopharmaceuticals based on various albumin binders. Compared to typical small molecule and peptide drugs, our products show significantly better tumor retention and tumor absorbed doses, making them more favorable for radionuclide therapy at reduced dose and with less frequent administrations. Since its establishment, LNC has built a relatively complete radionuclide diagnosis and treatment (radiotheranostics) pipeline, covering small molecule, peptides, and antibodies-based radioligands. LNC’s products address unmet clinical needs in diagnosing and treating multiple types of solid tumors, such as prostate cancer, gastric cancer, glioma, neuroendocrine tumors, lung cancer, thyroid cancer, etc. Among them, fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) related products have received IND approvals from US FDA, Singapore HSA and China NMPA and are in advanced stages of development, maintaining a global leading position.

Adhering to the concept of “Letting more patients benefit from innovation-driven radiotheranostics”, LNC has invited Dr. Richard Baum, a world-renowned expert in radiotheranostics, as LNC’s consultant. Under the leadership of our Co-Founder and Chief Scientific Officer (CSO) Prof. Xiaoyuan (Shawn) Chen and Chief Medical Officer (CMO) Prof. Jingjing Zhang, LNC has been in close collaboration with many well-known institutions worldwide to carry out both clinical trials and investigator-initiated trials (IITs). The research results have been published in top journals such as Nature Reviews Bioengineering, Journal of Nuclear Medicine, and European Journal of Nuclear Medicine and Molecular Imaging. The LNC team is striving to be at the forefront of nuclear medicine and radiopharmaceuticals field and is emerging as one of the global leaders in this highly competitive field.